eligibility_summary
Eligible: 18–75, ECOG 0–1, untreated gastric/EGJ adenoca (path‑confirmed) with laparoscopic peritoneal mets (PCI ≤20, limited ascites), surgery‑fit, adequate organs, wt ≥40 kg or BMI >18.5, WOCBP: neg test + contraception/no lactation, consent. Exclude: other cancer/transplant, bleeding/coagulation or anticoagulation, recent VTE/MI/arrhythmia/HF, renal/GI/effusion issues, HIV/TB/active infection/ILD, autoimmune disease or immunosuppression, live vaccine or prior immunotherapy, allergy/substance abuse, noncompliance.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Phase II single-arm trial in gastric/EGJ cancer with peritoneal metastasis tests: 1) HIPEC with paclitaxel (taxane, microtubule-stabilizing cytotoxic) delivered intraperitoneally at 43°C to enhance drug penetration and cytotoxicity to peritoneal tumor cells, 2) Systemic tirilizumab (anti–PD-1 monoclonal antibody, immune checkpoint inhibitor) to block the PD-1/PD-L1 axis and restore cytotoxic T-cell activity, 3) SOX chemotherapy: oxaliplatin (platinum DNA crosslinker) plus S-1/Tegeo (oral fluoropyrimidine, tegafur prodrug of 5-FU inhibiting thymidylate synthase, with modulators gimeracil/oteracil), 4) Trastuzumab/Herceptin (anti-HER2 monoclonal antibody, given for HER2+ tumors) blocking HER2 signaling and mediating ADCC. Targets/pathways: peritoneal tumor cells, microtubules, DNA crosslink repair, thymidylate synthase/DNA synthesis, HER2 (PI3K/AKT/MAPK), and PD-1 on T cells.